| Literature DB >> 34065478 |
Wenli Hu1, Chong Zhao1, Hongbo Hu1, Shutao Yin1.
Abstract
Selenium (Se) is an essential micronutrient for mammals, and its deficiency seriously threatens human health. A series of biofortification strategies have been developed to produce Se-enriched foods for combating Se deficiency. Although there have been some inconsistent results, extensive evidence has suggested that Se supplementation is beneficial for preventing and treating several chronic diseases. Understanding the association between Se and chronic diseases is essential for guiding clinical practice, developing effective public health policies, and ultimately counteracting health issues associated with Se deficiency. The current review will discuss the food sources of Se, biofortification strategies, metabolism and biological activities, clinical disorders and dietary reference intakes, as well as the relationship between Se and health outcomes, especially cardiovascular disease, diabetes, chronic inflammation, cancer, and fertility. Additionally, some concepts were proposed, there is a non-linear U-shaped dose-responsive relationship between Se status and health effects: subjects with a low baseline Se status can benefit from Se supplementation, while Se supplementation in populations with an adequate or high status may potentially increase the risk of some diseases. In addition, at supra-nutritional levels, methylated Se compounds exerted more promising cancer chemo-preventive efficacy in preclinical trials.Entities:
Keywords: baseline selenium status; chronic diseases; methylated selenium compounds; selenium biofortification
Year: 2021 PMID: 34065478 PMCID: PMC8160805 DOI: 10.3390/nu13051739
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Se biofortification strategies, predominant dietary Se forms, and their percent compositions in Se-enriched foods. Plant-based biofortification mainly consists of (a) genetic biofortification and agronomic biofortification, including (b) and (c). Genetic biofortification approaches include breeding and genetic engineering, which can transfer the Se-enriched genes, such as ATP-sulfurylase (APS) and selenocysteine methyltransferase (SMT), to plants. Different sources of Se are available for feed supplements for domestic animals to produce Se-biofortified animal foods (d), including inorganic (mainly selenite or selenate), organic (mainly Se yeast), and nanoforms of Se; Adding Se, such as selenite, to culture media of microbes (e) to manufacture Se-enriched foods, such as Se yeast.
Figure 2Se metabolism. Most dietary Se can be metabolized to H2Se, further involved in the synthesis of selenoproteins and methylated excretion. Methylselenol is a critical Se metabolite for anticancer activity. Se-methylselenocysteine and synthetic methylseleninic acid can be directly converted into methylselenol and bypass the H2Se pool. Based on Nicastro and Dunn, 2013 [42].
Mammalian selenoproteins with characterized functions. Based on Labunskyy et al., 2014; Davis et al., 2012; Avery and Hoffmann, 2018; Gladyshev et al., 2016 [44,45,46,47].
| Selenoprotein (Abbreviation) | Tissue Distribution a | Localization | Functions |
|---|---|---|---|
| Glutathione peroxidase 1 (GPX1) | Blood, kidney, liver, placenta | Cytosol | Reduces cellular H2O2 and lipid peroxides |
| Glutathione peroxidase 2 (GPX2) | Gastrointestinal tract, liver, | Cytosol | Reduces peroxide in the gut |
| Glutathione peroxidase 3 (GPX3) | Epididymis, kidney, plasma | Plasma | Reduces peroxide in blood |
| Glutathione peroxidase 4 (GPX4) | Liver, testis | Cytosol; mitochondria; nucleus | Reduces phospholipid peroxide |
| Glutathione peroxidase 6 (GPX6) | Embryos, olfactory epithelium | Cytosol | Reduces cellular H2O2 in the olfactory epithelium |
| Thioredoxin reductase 1 (TXNRD1) | Heart, kidney, liver | Cytosol | Regenerates reduced thioredoxin |
| Thioredoxin reductase 2 (TXNRD2) | Adrenal gland, heart, kidney, liver | Cytosol | Catalyzes a variety of reactions, specific for thioredoxin and glutaredoxin systems |
| Thioredoxin reductase 3 (TXNRD3) | Testis, heart, kidney, liver | Mitochondria | Reduces the oxidized form of thioredoxin and glutaredoxin 2 |
| Iodothyronine deiodinase 1 (DIO1) | Kidney, liver, thyroid | Plasma membrane | Important for systemic active thyroid hormone levels |
| Iodothyronine deiodinase 2 (DIO2) | Brain, brown adipose tissue, | Endothelial reticulum | Important for local active thyroid hormone levels |
| Iodothyronine deiodinase 3 (DIO3) | Brain, placenta, skin | Plasma membrane | Inactivates thyroid hormone |
| Methionine sulfoxide reductase B1 (MSRB1) | Liver, kidney | Cytosol | Reduces methionine- |
| Selenophosphate synthetase 2 (SEPHS2) | Kidney, liver, testis | Cytosol | Synthesis of selenophosphate |
| Selenoprotein F (SELENOF) | Liver, prostate | Endoplasmic reticulum (ER) | Involved in protein folding |
| Selenoprotein H (SELENOH) | Unknown b | Nucleus | Involved in redox sensing and transcription |
| Selenoprotein I | Unknown b | Membrane | Involved in phospholipid biosynthesis |
| Selenoprotein K (SELENOK) | Unknown b | ER membrane | Modulates Ca2+ influx that affects immune cell function; component |
| Selenoprotein M (SELENOM) | Brain | ER | Protein folding in ER |
| Selenoprotein N (SELENON) | Brain, heart, liver, muscle | ER membrane | Proper muscle development |
| Selenoprotein O (SELENOO) | Unknown b | Mitochondria | Unknown c |
| Selenoprotein P (SELENOP) | Liver, plasma | Plasma | Se transport and antioxidant function |
| Selenoprotein S | Unknown b | ER membrane | Involved in ER-associated degradation |
| Selenoprotein T | Unknown b | ER and Golgi | Involved in redox regulation and cell anchorage |
| Selenoprotein V (SELENOV) | Testes | Cytosol | Unknown c |
| Selenoprotein W (SELENOW) | Brain, muscle, testes | Cytosol | Necessary for muscle function |
a Selected rodent and human tissues in which selenoprotein expression is relatively high. b Protein expression is unknown. However, mRNA has been detected in several tissues. c Function is unknown. Discovered by in silico analysis.
Figure 3Possible mechanisms of Se against cancer and related molecular targets. Se has been shown to induce apoptosis, cell cycle arrests, inhibit angiogenesis, invasion and metastasis, potentiate anti-tumor immunity, stimulate DNA damage repair, induce autophagic cell death, suppress the androgen receptor (AR), estrogen receptor (ER) signaling, and modulate other processes involved in carcinogenesis.